

Supplemental Table S1. Clinical Characteristics of Patients Who Developed Pituitary Dysfunction under PD-1/CTLA-4-Abs Treatment with Pituitary Enlargement and Those without It

Pituitary enlargement	Yes (n=6)	No (n=10)	P value
Multiple hormone deficiency	6 (100.0)	3 (30.0)	0.011
Malignancy			0.008
MM	3 (50.0)	2 (20.0)	
NSCLC	2 (33.3)	2 (20.0)	
RCC	1 (16.7)	3 (30.0)	
Mesothelioma	0	3 (30.0)	
Ipilimumab			0.299
3 mg/kg	3 (50.0)	2 (20.0)	
1 mg/kg	3 (50.0)	8 (80.0)	
Ipilimumab cumulative dose, mg/kg	5.0	3.0	0.109
No. of cycles, times			
Ipilimumab	2.8±1.2	2.8±1.0	0.955
Nivolumab	3.0 (2.5–5.0)	3.5 (3.0–7.3)	0.461
Onset, day	67.5 (45–98)	136 (82–172)	0.030

Values are expressed as number (%), mean±standard deviation, or median (interquartile range).

PD-1/CTLA-4-Abs, PD-1-Ab plus CTLA-4-Ab combination therapy; PD-1-Ab, anti-programmed cell death-1 antibody; CTLA-4-Ab, anti-cytotoxic T-lymphocyte antigen-4 antibody; Multi-D, multiple pituitary hormone deficiency; IAD, isolated adrenocorticotrophic hormone deficiency; MM, malignant melanoma; NSCLC, non-small cell lung carcinoma; RCC, renal cell carcinoma.